Welcome to our dedicated page for Horizon Therapeutics Pub L news (Ticker: HZNP), a resource for investors and traders seeking the latest updates and insights on Horizon Therapeutics Pub L stock.
Horizon Therapeutics plc (NASDAQ: HZNP) is a global biotechnology leader focused on developing therapies for rare, autoimmune, and severe inflammatory diseases. This dedicated news hub provides investors and healthcare professionals with timely updates on regulatory milestones, research breakthroughs, and strategic corporate initiatives shaping the company's trajectory.
Access authoritative information on Horizon's innovative treatments like TEPEZZA® and KRYSTEXXA®, along with analysis of key developments including partnership announcements and regulatory filings. Our curated news collection serves as your primary resource for understanding Horizon's position in the biopharmaceutical landscape and its commitment to addressing unmet medical needs.
Key updates cover clinical trial progress, FDA communications, financial results, and major corporate events such as Horizon's pending acquisition by Amgen following FTC clearance. All content is sourced from official releases and verified channels to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined access to Horizon Therapeutics' evolving story. For additional context on the company's mission and pipeline, visit their official website at HorizonTherapeutics.com.
Horizon Therapeutics (Nasdaq: HZNP) presented vital information on Neuromyelitis Optica Spectrum Disorder (NMOSD) at the 7th Congress of the European Academy of Neurology from June 19-22, 2021. Key presentations included long-term safety and efficacy outcomes from the N-MOmentum trial and insights into immunoglobulin kinetics and infection risk. NMOSD is a severe autoimmune disease that necessitates ongoing management, affecting primarily women and individuals of African and Asian descent.
Horizon Therapeutics (Nasdaq: HZNP) announced its agreement to acquire a drug manufacturing facility from EirGen Pharma in Waterford, Ireland, for $65 million. The facility will enhance Horizon's in-house manufacturing capabilities for its rare disease biologics, including TEPEZZA and KRYSTEXXA. Plans are in place to work with regulatory agencies for necessary approvals, with the first product expected to be released in about two years. The acquisition will also include the transfer of approximately 40 employees and plans to recruit an additional 50 staff members by 2022.
Horizon Therapeutics (Nasdaq: HZNP) presented new data from the PROTECT study at the EULAR European Congress of Rheumatology, focusing on the efficacy of KRYSTEXXA (pegloticase) for treating uncontrolled gout in kidney transplant patients. The ongoing Phase 4 trial maintains stable kidney function and shows promising safety results. Among 10 patients, the mean eGFR improved from 41.6 to 43.8 mL/min/1.73 m². Patients reported significant reductions in pain and disability. The trial was fully enrolled in January 2021 and is expected to conclude in Fall 2021.
Horizon Therapeutics plc (Nasdaq: HZNP) announced the enrollment of the first patient in the ADVANCE trial, which examines the use of KRYSTEXXA (pegloticase injection) combined with methotrexate for patients with uncontrolled gout who did not respond to KRYSTEXXA alone. This open-label trial aims to enroll 30 patients and has a primary endpoint of maintaining serum uric acid levels below 6 mg/dL for at least 80% of Month 6. The safety and efficacy of this combined treatment are yet to be established by health authorities.
Horizon Therapeutics plc (Nasdaq: HZNP) will participate in two upcoming conferences: the Jefferies Virtual Health Care Conference on June 3, 2021, at 1 p.m. ET, and the BMO Biopharma Day on June 22, 2021, at 10 a.m. ET. Live webcasts of both presentations can be accessed on Horizon's website, with replays available afterward. Horizon focuses on developing medicines for rare, autoimmune, and severe inflammatory diseases, emphasizing a commitment to impactful therapies for patients.
Horizon Therapeutics plc (Nasdaq: HZNP) announced its data presentations at the EULAR European Congress of Rheumatology from June 2-5, 2021. The company will present findings on HZN-4920 (VIB4920), targeting rheumatoid arthritis, alongside updates on the PROTECT trial concerning KRYSTEXXA (pegloticase injection) for chronic gout patients, including those who have undergone kidney transplants. Horizon is committed to enhancing research in rheumatic diseases to inform treatment strategies and improve patient outcomes.
Horizon Therapeutics plc (Nasdaq: HZNP) ranked #1 in overall corporate reputation among U.S. patient groups that worked with the company, and #2 among those familiar with it, according to PatientView's annual survey of 207 patient groups evaluating 38 pharmaceutical companies. Horizon excelled in supporting patients during the COVID pandemic and demonstrating integrity, transparency, and effective patient-centered strategy. Globally, Horizon ranked #2 in overall reputation and top in multiple categories, reaffirming its commitment to improving lives through advocacy and partnerships.
Horizon Therapeutics plc (Nasdaq: HZNP) will participate in the Bank of America Securities 2021 Health Care Conference on May 11, 2021. The presentation is scheduled for 3:30 p.m. ET and will be available for live streaming on Horizon's website. A replay will also be accessible after the event. Horizon is dedicated to developing medicines for rare, autoimmune, and severe inflammatory diseases, emphasizing a combination of scientific innovation and compassion. For more details, visit www.horizontherapeutics.com.
Horizon Therapeutics plc (Nasdaq: HZNP) announced new findings from the Phase 2/3 N-MOmentum trial for UPLIZNA, revealing its potential to reduce worsening disability in NMOSD patients. Published in the May issue of Neurology Neuroimmunology & Neuroinflammation, these results underline UPLIZNA's role as the first FDA-approved anti-CD19 B-cell depleting therapy for NMOSD. Additionally, a separate analysis points to serum glial fibrillary acidic protein (sGFAP) as a novel biomarker for assessing disease activity in NMOSD, addressing limitations in current monitoring methods.
